WAYNE, Pa. — Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will present two...

Atlanta, Georgia – Treatment with Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) may help reverse pancreatic dysfunction in young children with cystic fibrosis (CF), challenging the long-held belief that this complication is irreversible. New findings presented by Vertex Pharmaceuticals, the therapy’s developer, at the North American Cystic Fibrosis Conference (NACFC) showed improvements in pancreatic function...

PITTSBURGH, PA — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today a positive clinical update supporting initial proof of concept for KB113, an intratumoral immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance, in the...